Loss of YTHDF1 in classical dendritic cells increases cross-presentation of tumor antigens and antigen-specific CD8+ T cell antitumor responses, through boosting PD-L1 checkpoint blockade’s therapeutic efficacy. The gene discussed is CD274; the disease is neoplasm.